RxDoctor Payments DataLook up a doctor →

Charles Harper, MD

Internal Medicine · Norfolk, NENPI 1063620961

Payments from drug & device makers

$31,082,219in general payments, 2019–2025

Across 5,327 payments — averaging $5834.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$15.4M
  • Pfizer$6.7M
  • Sanofi Pasteur Inc.$2.6M
  • Seqirus USA Inc$2.4M
  • Janssen Research & Development, LLC$805K
  • Merck$705K
  • plus $2.4M from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.3,045$15,373,933
Pfizer414$6,720,676
Sanofi Pasteur Inc.62$2,623,970
Seqirus USA Inc662$2,429,326
Janssen Research & Development, LLC101$805,314
Merck35$705,026
Bavarian Nordic A/s69$533,352
Novavax Inc68$445,541
AbbVie(2 entities)87$396,093
Johnson & Johnson72$323,866
GSK92$273,020
Vertex4$240,453
Boehringer Ingelheim71$40,223
AstraZeneca63$39,316
Sanofi US Services Inc.13$39,170
E.r. Squibb & Sons, L.L.C.10$34,380
Biogen1$19,323
Bayer34$13,158
Biohaven Pharmaceuticals, Inc.19$11,090
Ironwood Pharmaceuticals, Inc8$3,702
Boehringer Ingelheim Limited1$2,356
Boehringer Ingelheim Pharma GmbH & Co.kg2$1,482
Lilly USA, LLC89$1,070
Lexicon Pharmaceuticals, Inc.2$993
Novo Nordisk65$908
Amgen47$707
H. Lundbeck A S1$617
Sanofi-aventis U.S. LLC20$353
Amarin Pharma, Inc.18$282
Xeris Pharmaceuticals, Inc.17$276
Mannkind Corporation16$256
Avanir Pharmaceuticals, Inc.11$160
Novartis10$149
Takeda Pharmaceuticals U.S.A., Inc.8$140
Astellas Pharma US Inc10$135
Aimmune Therapeutics, Inc.3$134
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$128
Daiichi Sankyo Inc.7$115
Biohaven Pharmaceutical Holding Company Ltd.7$115
Arbor Pharmaceuticals, Inc.7$108
Corcept Therapeutics5$94
Otsuka America Pharmaceutical, Inc.6$94
Axsome Therapeutics, Inc.4$80
Abbott4$66
Bristol Myers Squibb3$53
Lundbeck LLC2$40
Phathom Pharmaceuticals, Inc.5$35
Radius Health, Inc.2$32
Idorsia Pharmaceuticals US Inc2$28
Vanda Pharmaceuticals Inc.1$25
Boston Scientific1$24
Forte Bio-pharma LLC1$21
Kyowa Kirin, Inc.1$20
Teva Pharmaceuticals USA, Inc.1$20
Tonix Medicines, Inc.1$19
Mallinckrodt Hospital Products Inc.1$19
Scpharmaceuticals Inc.1$19
Sumitomo Pharma America, Inc.1$18
Medtronic1$18
Sanofi1$17

How this compares

$31,082,219 in reported general payments places this provider in the 95th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$327,421
Medicare patients
546
Services billed
27,389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Norfolk

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →